论文部分内容阅读
目的:分析和比较去甲氧柔红霉素(IDA)与柔红霉素(DNR)、米托蒽醌(MTN)治疗急性白血病的疗效和毒副反应。方法:将32例急性白血病患者分为两组,治疗组18例用IDA加阿糖胞苷(Ara蛳C)治疗,对照组14例用DNR或MTN加Ara蛳C治疗,两组均用标准3+7方案。结果:治疗组和对照组完全缓解率(CR)分别为66.7 %和43.8 %,总有效率(RR)分别为83.3 %和64.2 %。两组CR率和RR率差异有显著性(P<0.05)。治疗组骨髓抑制时间较对照组长(P<0.05),心脏毒性较小,其他毒副反应发生率基本相似。结论:去甲氧柔红霉素是效果可靠的抗白血病药物,以IDA组成联合化疗方案治疗急性白血病具有较好的疗效。
Objective: To analyze and compare the efficacy and side effects of IDA with DNR and MTN in the treatment of acute leukemia. Methods: Thirty-two patients with acute leukemia were divided into two groups. The treatment group (18 cases) was treated with IDA plus cytarabine (Ara 蛳 C) and the control group (14 cases) treated with DNR or MTN plus Ara 蛳 C 3 + 7 program. Results: The complete response rate (CR) of the treatment group and the control group were 66.7% and 43.8% respectively, and the total effective rate (RR) was 83.3% and 64.2% respectively. There was a significant difference between the two groups in CR rate and RR rate (P <0.05). The bone marrow suppression time of the treatment group was longer than that of the control group (P <0.05), the cardiotoxicity was small, and the incidence of other toxic and side effects was similar. Conclusion: Daunorubicin is a reliable anti-leukemia drug and has a good effect in the treatment of acute leukemia with IDA combined with chemotherapy.